77 male known CKD, uncontrolled hypertension suggest medication
Reading File
Finding Sources
Finding Sources
Searching PubMed
"hypertension" AND "chronic kidney disease" AND "antihypertensive"
Reading File
Reading File
Reading File
Reading File
Finding Sources
I now have comprehensive information to provide a detailed, well-structured answer. Here is the medication recommendation for this patient:
Antihypertensive Management: 77-Year-Old Male with CKD and Uncontrolled Hypertension
BP Target
Goal: SBP <130 mmHg / DBP <80 mmHg
For adults ≥65 years, achieving SBP <130 mmHg is the primary target. For older adults with high comorbidity burden and limited life expectancy, clinical judgment and patient preference should guide intensity of treatment. In this patient with CKD, the ACC/AHA 2017 target of <130/80 mmHg is the standard benchmark.
(Harrison's Principles of Internal Medicine, 22E, p. 2190)
Step-by-Step Drug Therapy
🥇 First-Line (Start here — most patients need combination)
| Drug Class | Agents | Why Use |
|---|---|---|
| ACE Inhibitor | Ramipril 2.5–10 mg OD, Perindopril 4–8 mg OD | Reduces intraglomerular pressure via efferent arteriolar dilation; slows CKD progression; reduces proteinuria |
| ARB (if ACEi not tolerated) | Losartan 50–100 mg OD, Telmisartan 40–80 mg OD | Same renoprotective mechanism; preferred over ACEi if cough occurs |
| Calcium Channel Blocker (CCB) | Amlodipine 5–10 mg OD | Good safety profile in CKD; safe in combination with ACEi/ARB; dilates afferent arteriole |
| Diuretic | Chlorthalidone 12.5–25 mg OD (if eGFR ≥30) | Addresses volume overload component of CKD hypertension; chlorthalidone preferred over HCTZ |
Practical note: Most CKD patients with uncontrolled hypertension require 3 agents to reach target. A typical starting triple combination: ACEi + CCB + Chlorthalidone.
⚠️ Diuretic Selection by eGFR
| eGFR | Preferred Diuretic |
|---|---|
| ≥30 mL/min/1.73 m² | Thiazide-like (chlorthalidone, indapamide) |
| <30 mL/min/1.73 m² | Loop diuretic (furosemide 20–80 mg, torsemide) |
Recent RCT evidence shows chlorthalidone achieved 10.5 mmHg lower ambulatory BP vs placebo even in stage 4 CKD (avg eGFR <23), also halving the urinary albumin/creatinine ratio. (Harrison's, p. 2190)
🔴 Resistant Hypertension (if BP remains >130/80 on 3 agents)
Add a mineralocorticoid receptor antagonist (MRA):
- Spironolactone 25–50 mg OD (cheapest, most evidence)
- Eplerenone 25–50 mg OD (less gynecomastia)
- Finerenone (non-steroidal, selective — preferred in CKD as it causes less hyperkalemia and has added renal/CV benefit; FDA-approved for CKD with T2DM)
⚠️ Monitor potassium closely with any RAAS-blocking agent (ACEi/ARB/MRA). Never combine ACEi + ARB — dangerous hyperkalemia and AKI risk.
Other Add-On Agents
| Drug | Use When |
|---|---|
| Beta-blocker (carvedilol, bisoprolol) | Concurrent CAD, heart failure, AF |
| Alpha-blocker (doxazosin) | Concurrent BPH (relevant in 77M) |
| Central agents (clonidine, moxonidine) | Refractory cases; adjunct |
Avoid pure vasodilators (e.g., minoxidil) — risk of volume overload and pericardial effusion. (Comprehensive Clinical Nephrology, 7E)
Non-Pharmacological Measures (Essential Adjuncts)
- Sodium restriction (<2 g/day Na)
- Fluid management (avoid sodium overload)
- Weight loss if obese
- Screen for obstructive sleep apnea — present in ~50% of CKD stages 4–5; a major cause of resistant hypertension
- Reduce alcohol, stop smoking
- Regular physical activity as tolerated
Monitoring in This Patient
| Parameter | Frequency |
|---|---|
| Serum creatinine + eGFR | 1–2 weeks after starting/titrating ACEi/ARB, then 3-monthly |
| Serum potassium | Same schedule; especially important in elderly |
| Ambulatory BP | To exclude white-coat hypertension as a cause of apparent resistance |
| Urine ACR (albumin/creatinine ratio) | Every 6 months |
Key Safety Notes for the Elderly
- Orthostatic hypotension — check lying/standing BP before each titration; more common in elderly with autonomic dysfunction
- Avoid dual RAAS blockade (ACEi + ARB) — hyperkalemia, AKI
- Hyperkalemia risk is amplified at older age + reduced eGFR; potassium <5.5 mEq/L should be maintained before initiating/up-titrating RAAS agents
- Start low, go slow with titration
- Refer to nephrology if hypertension remains refractory to ≥4 agents at therapeutic doses
Sources:
- Comprehensive Clinical Nephrology, 7th Edition — Hypertension chapter
- Harrison's Principles of Internal Medicine, 22E — Pharmacologic Therapy, CKD section (pp. 2189–2190)
- Brenner and Rector's The Kidney — HYPERTENSION chapter
- ERA synopsis of 2023 ESH Hypertension Guidelines for CKD (PMID: 38365947) — Practice Guideline, 2024
- Cochrane SR on BP targets in CKD (PMID: 39403990) — 2024
This is a shared conversation. Sign in to Orris to start your own chat.